Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
View Patent ↗Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
1. A pharmaceutical composition, comprising an aqueous solution of about 500 mg/ml sodium gamma-hydroxybutyrate, wherein the composition has a pH of about 7.3 to about 8.5, wherein the composition is chemically stable and resistant to microbial growth, and wherein the composition is free of preservatives.
2. The pharmaceutical composition of claim 1 , wherein the composition has a pH of about 7.5.
3. The pharmaceutical composition of claim 1 , wherein the composition has a pH of about 8.0.
4. The pharmaceutical composition of claim 1 , wherein the composition has a pH of about 8.5.
5. The pharmaceutical composition of claim 1 , wherein the composition additionally comprises a pH adjusting or buffering agent.
6. The pharmaceutical composition of claim 5 , wherein the pH adjusting or buffering agent is an acid.
7. The pharmaceutical composition of claim 6 , wherein the acid is an inorganic acid.
8. The pharmaceutical composition of claim 6 , wherein the acid is an organic acid.
9. The pharmaceutical composition of claim 6 , wherein the acid is selected from the group consisting of malic acid, citric acid, acetic acid, boric acid, lactic acid, hydrochloric acid, phosphoric acid, sulfuric acid, and nitric acid.
10. The pharmaceutical composition of claim 6 , wherein the acid is malic acid.
11. A method of treating cataplexy or daytime sleepiness in a patient having narcolepsy comprising diluting the pharmaceutical composition of claim 1 , and administering to the patient the diluted pharmaceutical composition.
12. The method of claim 11 , wherein the pharmaceutical composition is administered orally.
13. The method of claim 12 , wherein the pharmaceutical composition is administered orally as two consecutive single doses daily.
14. The method of claim 13 , wherein the first dose is administered prior to bedtime and the second dose is administered from about 2.5 to about 4.0 hours after administration of the first dose.
15. A set comprising the pharmaceutical composition of claim 1 in one or more container means.
16. The set of claim 15 , wherein the one or more container means are selected from the group consisting of a drinking cup, a dosing cup, a syringe, a pipette, a vial, an ampule, a test tube, a flask, a bottle, and a pouch syringe.
17. The set of claim 15 , comprising a third container means capable of retaining a first container means, a second container means, and one or more delivery vehicles capable of administering the pharmaceutical composition to the patient.
18. The set of claim 17 , wherein the first container means comprises the pharmaceutical composition, and the second container means comprises a diluent.